Steve Gavel

If you're going to BioTechX US, stop by and visit Gary Schneider, MSPH, ScD, founder of Delve-RW. Find us in the Start-Up Village, Booth S7. We’re particularly interested in your thoughts regarding barriers to efficient RWE study planning, conduct, QC, and dissemination. Also ask us about our Protocol and SAP Reviews. #pharmacoepidemiology #realworlddata #realworldevidence #RWD #RWE

Majority Considering Jobs Outside Biopharma, BioSpace Report Finds Most biopharma professionals are considering jobs outside of biotech and pharma, according to the new BioSpace Job Market Trends report. Based on a survey that closed this month, the report found that 59% of employed respondents and 76% of unemployed respondents are considering positions in other fields. Some age groups are more likely than others to consider jobs outside of biopharma. Employed survey respondents ages 25 to 34 and 35 to 44 are most likely (60% each), while those 45 to 54 (56%) are least likely. Unemployed survey respondents have a wider range of likelihood for considering jobs outside of biotech and pharma. Those ages 25 to 34 (64%) are least likely, while those 18 to 24 (88%) are most likely. https://lnkd.in/gwdK-H3E #aspenalert #biotech #bioprocess

LucidQuest Strategic Insights (lqventures.com) >>> Gene&Cell Therapy >> At Third Arc Bio, former J&J leaders raise $165M to test oncology, autoimmune biologics: After more than a decade steering Johnson & Johnson’s oncology drug R&D, Peter Lebowitz is ready for his next challenge: shepherding the “third arc” of biologics development. “The first one was single targets for the antibody and binding to a cytokine or cell surface receptor. The second one was engineering those antibodies a little differently, either modifying the Fc, putting on a toxin, putting on a radioconjugate,” Lebowitz said in an interview with Endpoints News. “The third is multispecific antibodies that actually bind to different cell types and bring in new biology.” In that vein, Lebowitz is now running a new biologics startup named Third Arc Bio founded by another former J&J leader: Sanjaya Singh. The company raised a $165 million Series A that will be used to move three experimental multispecific antibodies for solid tumors and inflammatory and immunology (I&I) diseases into the clinic. The unveiling was announced the same morning as the launch of another biologics-focused oncology and immunology biotech. Earlier on Tuesday, Flagship Pioneering took the wraps off a $50 million commitment to its Abiologics offshoot. Founded in 2022, Third Arc Bio is working on multispecific antibodies for solid tumors, inflammatory bowel disease, rheumatoid arthritis, lupus and so-called Th2 diseases, which entail a broad scope of inflammatory conditions, according to Lebowitz. “At J&J, I saw all the platforms. We had them all. I specifically wanted to work on [multispecific antibodies] because this is the area where there is the largest opportunity to meet unmet need,” Lebowitz said. “There’s a lot of interest in ADCs now, and ADCs are very important. But this is the area that is right in the right spot of the breaking point where it goes over the edge and actually is transformational for solid tumors.” He “retired” from J&J on Jan. 1 and joined Third Arc as CEO on Jan. 2. In his role as head of oncology R&D, Lebowitz solidified the pharma giant’s work in CAR-T cell therapies with partner Legend Biotech and oversaw a series of wins in multiple myeloma, among other areas of oncology. While at J&J, he worked with Third Arc founder and chief scientific officer Singh, in addition to chief operating officer Joe Erhardt. The trio has “collectively delivered 19 new medicines,” Lebowitz said. Debi Watson, another longtime J&J leader, is the startup’s chief business officer. ‘Atypical Series A’ Oncology remains a big area of investment for biotech venture capitalists, and I&I continues to drum up large financings and M&A deals. With a pipeline spanning both areas, Third Arc was able to attract the 58th private biotech megaround of 2024, according to Endpoints’ ongoing tally.… #lucidquest #genetherapy #celltherapy